Nexentis Technologies has taken a step from computer screens toward the lab bench: its wholly owned subsidiary MitoCareX Bio has selected and ordered molecules for planned laboratory testing in a drug-discovery program

1

2

. The experiments are still plans, with no work started.

How the molecules were chosen

The work sits under a drug-discovery initiative between MitoCareX Bio and Boltz, a public-benefit AI research lab working on biomolecular foundation models. The initiative pairs MitoCareX's discovery work with Boltz's AI models to find potential small-molecule starting points for chosen programs

1

2

.

The selection came after additional computational prioritization of results from an initial screening stage finished on October 29, 2026

1

2

. The company described the preliminary predictions at the time as encouraging for further analysis and experimental work

2

.

What the tests are for

The stated purpose is gathering evidence to guide a decision about which molecules, if any, deserve further work

1

2

.

The gap between the announcement and the lab is wide for now. The molecules have not been received, testing has not begun, and the company gave no timeline for either

1

2

. The company itself cautions that the computational predictions remain experimentally unvalidated and that ordering molecules is no evidence any of them have biological activity

1

2

.

© 2026 TheOutpost.AI All rights reserved